Pharmaceuticals Global On demand · 24-48h

Global Next Generation Drug Conjugates (NDCs) Market Strategic Research Report

Global Next Generation Drug Conjugates (NDCs) Market Strateg…

$3,500 USD

Strategic Research Report

Global Next Generation Drug Conjugates (NDCs) Market

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Enhertu, Pluvicto, Amvuttra, Trodelvy, Sacituzumab Tirumotecan, Patritumab Deruxtecan, 225Ac-PSMA-617, Other Commercialized Products, Other Pipeline Products

By Application: Breast Cancer, Hattr with Polyneuropathy, Prostate Cancer, Primary Hyperlipidemia, Other Indications

Key Players: AstraZeneca, Daiichi Sankyo, Company Limited, Novartis AG, Alnylam Pharmaceuticals, Inc, Gilead Sciences, Inc, AbbVie, Inc., Ionis Pharmaceuticals, Inc., Sanofi, Rakuten Group, Inc., Novo Nordisk, ADC Therapeutics SA, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals Inc., Bicycle Therapeutics, Avidity Biosciences, Silence Therapeutics, Medilink Therapeutics, Systimmune, Inc., Actinium Pharmaceuticals, Alphamab Oncology, Fusion Pharma, Orano Group, Pepgen INC, Tubulis GmbH, Clarity Pharmaceuticals

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2024 · forecast to 2032

Length: 150 pages

Overview

Scope of the Report

Covering the period 2026 to 2032, this report looks at the global Next Generation Drug Conjugates (NDCs) market from the viewpoint of the companies that supply it, the customers that buy from it and the investors that follow it.

Analysis starts from a global definition of the market, then moves to segment-level outlooks by type and application, and finishes with regional and country-level forecasts.

Market Segmentation

Segmentation of the global Next Generation Drug Conjugates (NDCs) market covers the dimensions below, with a forecast for every segment:

By Product: Enhertu, Pluvicto, Amvuttra, Trodelvy, Sacituzumab Tirumotecan, Patritumab Deruxtecan, 225Ac-PSMA-617, Other Commercialized Products and Other Pipeline Products
By Type: Antibody–small Molecule Conjugates, Peptide–radionuclide Conjugates, Ligand–oligonucleotide Conjugates and Other Drug Conjugates
By Target Ligand: Antibodies, Amino Sugars, Small Molecules and Peptides
By Payload Type: Small-molecule Payloads, Oligonucleotide Payloads and Radionuclide Payloads
By Indication: Breast Cancer, Hattr with Polyneuropathy, Prostate Cancer, Primary Hyperlipidemia and Other Indications

Regional analysis covers Asia Pacific, North America, Europe, the Middle East and Africa and Latin America, with country-level forecasts.

Market Context

Companies in pharmaceuticals typically manage long development timelines, quality and supply-chain compliance, and market-access negotiations country by country. Participants in Next Generation Drug Conjugates (NDCs) are generally differentiated by the strength of their clinical data, portfolio, regulatory track record and market-access capabilities.

Competitive Landscape

The competitive analysis profiles 25 companies active in the Next Generation Drug Conjugates (NDCs) market: AstraZeneca, Daiichi Sankyo, Company Limited, Novartis AG, Alnylam Pharmaceuticals, Inc, Gilead Sciences, Inc, AbbVie, Inc., Ionis Pharmaceuticals, Inc., Sanofi, Rakuten Group, Inc., Novo Nordisk, ADC Therapeutics SA, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals Inc., Bicycle Therapeutics, Avidity Biosciences, Silence Therapeutics, Medilink Therapeutics, Systimmune, Inc., Actinium Pharmaceuticals, Alphamab Oncology, Fusion Pharma, Orano Group, Pepgen INC, Tubulis GmbH and Clarity Pharmaceuticals.

Profiles follow a consistent structure: overview, products and segments, financial performance, strategy, SWOT analysis and strategic implications.

What the Report Covers

The report is organised into the following areas:

How the Next Generation Drug Conjugates (NDCs) market is defined, how large it is and how it is forecast to grow from 2026 to 2032
Segment outlook by type and by application
Regional outlook for five regions and country-level forecasts for 20 countries
Growth drivers and inhibitors, with an assessment of how strongly each affects the outlook
Company profiles and the competitive landscape, including competitive intensity and key player strategies
Porter's Five Forces, PESTLE and SWOT analysis
Future trends, technology and innovation, and the investment and M&A outlook

This is an on-demand title: the report is compiled to the scope above and delivered in PDF within 24 to 48 hours of purchase.

Key Questions Answered

How large is the global Next Generation Drug Conjugates (NDCs) market today, and how is it expected to grow between 2026 and 2032?
What is driving demand for Next Generation Drug Conjugates (NDCs), and what could slow growth?
Which product segments of Next Generation Drug Conjugates (NDCs) - Enhertu, Pluvicto and Amvuttra - are positioned for the strongest growth?
How does the Next Generation Drug Conjugates (NDCs) market differ by type (Antibody–small Molecule Conjugates, Peptide–radionuclide Conjugates and Ligand–oligonucleotide Conjugates)?
How do AstraZeneca, Daiichi Sankyo, Company Limited and Novartis AG and the other profiled companies compare on positioning and strategy in Next Generation Drug Conjugates (NDCs)?
Which regions and countries are the largest and fastest-growing markets for Next Generation Drug Conjugates (NDCs)?

Who Can Use This Report

Developers, manufacturers and providers benchmarking their position in Next Generation Drug Conjugates (NDCs) and planning portfolio, market-access and partnership strategy
Customers, distributors and channel partners such as Breast Cancer, Hattr with Polyneuropathy and Prostate Cancer evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type

EnhertuPluvictoAmvuttraTrodelvySacituzumab TirumotecanPatritumab Deruxtecan225Ac-PSMA-617Other Commercialized ProductsOther Pipeline Products

By Application

Breast CancerHattr with PolyneuropathyProstate CancerPrimary HyperlipidemiaOther Indications

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Segment Outlook by Product
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Target Ligand
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Product

3.1 Market Segmentation by Product
3.1.1 Market by Product Overview
3.1.2 Enhertu
3.1.3 Pluvicto
3.1.4 Amvuttra
3.1.5 Trodelvy
3.1.6 Sacituzumab Tirumotecan
3.1.7 Patritumab Deruxtecan
3.1.8 225Ac-PSMA-617
3.1.9 Other Commercialized Products
3.1.10 Other Pipeline Products

04Market Segmentation by Type

4.1 Market Segmentation by Type
4.1.1 Market by Type Overview
4.1.2 Antibody–small Molecule Conjugates
4.1.3 Peptide–radionuclide Conjugates
4.1.4 Ligand–oligonucleotide Conjugates
4.1.5 Other Drug Conjugates

05Market Segmentation by Target Ligand

5.1 Market Segmentation by Target Ligand
5.1.1 Market by Target Ligand Overview
5.1.2 Antibodies
5.1.3 Amino Sugars
5.1.4 Small Molecules
5.1.5 Peptides

06Market Segmentation by Payload Type

6.1 Market Segmentation by Payload Type
6.1.1 Market by Payload Type Overview
6.1.2 Small-molecule Payloads
6.1.3 Oligonucleotide Payloads
6.1.4 Radionuclide Payloads

07Market Segmentation by Indication

7.1 Market Segmentation by Indication
7.1.1 Market by Indication Overview
7.1.2 Breast Cancer
7.1.3 Hattr with Polyneuropathy
7.1.4 Prostate Cancer
7.1.5 Primary Hyperlipidemia
7.1.6 Other Indications

08Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

09Country-Level Market Forecast

9.1 Asia Pacific
9.1.1 China
9.1.2 Japan
9.1.3 India
9.1.4 South Korea
9.1.5 Australia
9.1.6 Rest of Asia Pacific
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Rest of North America
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Middle East & Africa
9.4.1 GCC Countries
9.4.2 Rest of Middle East & Africa
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America

10Growth Drivers & Inhibitors

10.1 Growth Drivers & Inhibitors
10.1.1 Section Overview
10.1.2 Growth Drivers
10.1.3 Growth Inhibitors
10.1.4 Driver and Inhibitor Impact Assessment
10.1.5 Analyst Perspective

11Key Company Profiles

11.1 AstraZeneca
11.1.1 Company Overview
11.1.2 Key Products & Segments
11.1.3 Financial Performance (2023–2025)
11.1.4 Business Strategy
11.1.5 SWOT Analysis
11.1.6 Strategic Implications (2026–2032)
11.2 Daiichi Sankyo, Company Limited
11.2.1 Company Overview
11.2.2 Key Products & Segments
11.2.3 Financial Performance (2023–2025)
11.2.4 Business Strategy
11.2.5 SWOT Analysis
11.2.6 Strategic Implications (2026–2032)
11.3 Novartis AG
11.3.1 Company Overview
11.3.2 Key Products & Segments
11.3.3 Financial Performance (2023–2025)
11.3.4 Business Strategy
11.3.5 SWOT Analysis
11.3.6 Strategic Implications (2026–2032)
11.4 Alnylam Pharmaceuticals, Inc
11.4.1 Company Overview
11.4.2 Key Products & Segments
11.4.3 Financial Performance (2023–2025)
11.4.4 Business Strategy
11.4.5 SWOT Analysis
11.4.6 Strategic Implications (2026–2032)
11.5 Gilead Sciences, Inc
11.5.1 Company Overview
11.5.2 Key Products & Segments
11.5.3 Financial Performance (2023–2025)
11.5.4 Business Strategy
11.5.5 SWOT Analysis
11.5.6 Strategic Implications (2026–2032)
11.6 AbbVie, Inc.
11.6.1 Company Overview
11.6.2 Key Products & Segments
11.6.3 Financial Performance (2023–2025)
11.6.4 Business Strategy
11.6.5 SWOT Analysis
11.6.6 Strategic Implications (2026–2032)
11.7 Ionis Pharmaceuticals, Inc.
11.7.1 Company Overview
11.7.2 Key Products & Segments
11.7.3 Financial Performance (2023–2025)
11.7.4 Business Strategy
11.7.5 SWOT Analysis
11.7.6 Strategic Implications (2026–2032)
11.8 Sanofi
11.8.1 Company Overview
11.8.2 Key Products & Segments
11.8.3 Financial Performance (2023–2025)
11.8.4 Business Strategy
11.8.5 SWOT Analysis
11.8.6 Strategic Implications (2026–2032)
11.9 Rakuten Group, Inc.
11.9.1 Company Overview
11.9.2 Key Products & Segments
11.9.3 Financial Performance (2023–2025)
11.9.4 Business Strategy
11.9.5 SWOT Analysis
11.9.6 Strategic Implications (2026–2032)
11.10 Novo Nordisk
11.10.1 Company Overview
11.10.2 Key Products & Segments
11.10.3 Financial Performance (2023–2025)
11.10.4 Business Strategy
11.10.5 SWOT Analysis
11.10.6 Strategic Implications (2026–2032)
11.11 ADC Therapeutics SA
11.11.1 Company Overview
11.11.2 Key Products & Segments
11.11.3 Financial Performance (2023–2025)
11.11.4 Business Strategy
11.11.5 SWOT Analysis
11.11.6 Strategic Implications (2026–2032)
11.12 Arrowhead Pharmaceuticals
11.12.1 Company Overview
11.12.2 Key Products & Segments
11.12.3 Financial Performance (2023–2025)
11.12.4 Business Strategy
11.12.5 SWOT Analysis
11.12.6 Strategic Implications (2026–2032)
11.13 Regeneron Pharmaceuticals Inc.
11.13.1 Company Overview
11.13.2 Key Products & Segments
11.13.3 Financial Performance (2023–2025)
11.13.4 Business Strategy
11.13.5 SWOT Analysis
11.13.6 Strategic Implications (2026–2032)
11.14 Bicycle Therapeutics
11.14.1 Company Overview
11.14.2 Key Products & Segments
11.14.3 Financial Performance (2023–2025)
11.14.4 Business Strategy
11.14.5 SWOT Analysis
11.14.6 Strategic Implications (2026–2032)
11.15 Avidity Biosciences
11.15.1 Company Overview
11.15.2 Key Products & Segments
11.15.3 Financial Performance (2023–2025)
11.15.4 Business Strategy
11.15.5 SWOT Analysis
11.15.6 Strategic Implications (2026–2032)
11.16 Silence Therapeutics
11.16.1 Company Overview
11.16.2 Key Products & Segments
11.16.3 Financial Performance (2023–2025)
11.16.4 Business Strategy
11.16.5 SWOT Analysis
11.16.6 Strategic Implications (2026–2032)
11.17 Medilink Therapeutics
11.17.1 Company Overview
11.17.2 Key Products & Segments
11.17.3 Financial Performance (2023–2025)
11.17.4 Business Strategy
11.17.5 SWOT Analysis
11.17.6 Strategic Implications (2026–2032)
11.18 Systimmune, Inc.
11.18.1 Company Overview
11.18.2 Key Products & Segments
11.18.3 Financial Performance (2023–2025)
11.18.4 Business Strategy
11.18.5 SWOT Analysis
11.18.6 Strategic Implications (2026–2032)
11.19 Actinium Pharmaceuticals
11.19.1 Company Overview
11.19.2 Key Products & Segments
11.19.3 Financial Performance (2023–2025)
11.19.4 Business Strategy
11.19.5 SWOT Analysis
11.19.6 Strategic Implications (2026–2032)
11.20 Alphamab Oncology
11.20.1 Company Overview
11.20.2 Key Products & Segments
11.20.3 Financial Performance (2023–2025)
11.20.4 Business Strategy
11.20.5 SWOT Analysis
11.20.6 Strategic Implications (2026–2032)
11.21 Fusion Pharma
11.21.1 Company Overview
11.21.2 Key Products & Segments
11.21.3 Financial Performance (2023–2025)
11.21.4 Business Strategy
11.21.5 SWOT Analysis
11.21.6 Strategic Implications (2026–2032)
11.22 Orano Group
11.22.1 Company Overview
11.22.2 Key Products & Segments
11.22.3 Financial Performance (2023–2025)
11.22.4 Business Strategy
11.22.5 SWOT Analysis
11.22.6 Strategic Implications (2026–2032)
11.23 Pepgen INC
11.23.1 Company Overview
11.23.2 Key Products & Segments
11.23.3 Financial Performance (2023–2025)
11.23.4 Business Strategy
11.23.5 SWOT Analysis
11.23.6 Strategic Implications (2026–2032)
11.24 Tubulis GmbH
11.24.1 Company Overview
11.24.2 Key Products & Segments
11.24.3 Financial Performance (2023–2025)
11.24.4 Business Strategy
11.24.5 SWOT Analysis
11.24.6 Strategic Implications (2026–2032)
11.25 Clarity Pharmaceuticals
11.25.1 Company Overview
11.25.2 Key Products & Segments
11.25.3 Financial Performance (2023–2025)
11.25.4 Business Strategy
11.25.5 SWOT Analysis
11.25.6 Strategic Implications (2026–2032)

12Competitive Landscape

12.1 Competitive Landscape Overview
12.2 Competitive Intensity Assessment
12.3 Key Player Strategies & Positioning
12.4 Competitive Dynamics & Strategic Outlook
12.4.1 Emerging Competitive Threats
12.4.2 Consolidation vs. Fragmentation Outlook
12.4.3 Competitive Response Matrix
12.4.4 Strategic Recommendations, 2026–2032

13Porter's Five Forces Analysis

13.1 Threat of New Entrants
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Threat of Substitutes
13.5 Competitive Rivalry

14PESTLE Analysis

14.1 Political
14.2 Economic
14.3 Social and Demographic
14.4 Technological
14.5 Legal and Regulatory
14.6 Environmental
14.7 Strategic Implications of the PESTLE Assessment

15SWOT Analysis

16Future Trends & Outlook

16.1 Future Trends & Outlook
16.1.1 Trend Summary and Commercial Maturity Assessment
16.1.2 Technology and Innovation Trends
16.1.3 Long-Term Market Outlook
16.1.4 Investment & M&A Activity Outlook
16.1.5 Overall Outlook Assessment

Frequently asked questions

Which regions and countries are covered for Next Generation Drug Conjugates (NDCs)?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, US, Canada, Germany, UK, GCC Countries and Brazil.

How is the Next Generation Drug Conjugates (NDCs) market segmented?

The market is segmented by Product (Enhertu, Pluvicto, Amvuttra, Trodelvy, Sacituzumab Tirumotecan, Patritumab Deruxtecan and 3 more), Type (Antibody–small Molecule Conjugates, Peptide–radionuclide Conjugates, Ligand–oligonucleotide Conjugates and Other Drug Conjugates), Target Ligand (Antibodies, Amino Sugars, Small Molecules and Peptides), Payload Type (Small-molecule Payloads, Oligonucleotide Payloads and Radionuclide Payloads) and Indication (Breast Cancer, Hattr with Polyneuropathy, Prostate Cancer, Primary Hyperlipidemia and Other Indications), with forecasts for each segment.

Which companies are profiled in the Next Generation Drug Conjugates (NDCs) market report?

Key players profiled include AstraZeneca, Daiichi Sankyo, Company, Novartis AG, Alnylam Pharmaceuticals, Gilead Sciences, AbbVie, Ionis Pharmaceuticals, Sanofi, Rakuten Group, Novo Nordisk and 15 more, among 25 companies covered in total.

Who should buy the Next Generation Drug Conjugates (NDCs) market report?

The report is intended for manufacturers and solution providers, distributors and end users, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Next Generation Drug Conjugates (NDCs) market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license

from $3,500.00

Optional add-ons

Word Document (DOCX) +$500 PowerPoint Slides +$500 Excel Data Sheet +$500 Language Translation +$750

On demand · delivered within 24-48 hours

Secure checkout · SSL encrypted

License terms included

Post-purchase analyst support

Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →

Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600

Global Next Generation Drug Conjugates (NDCs) Market Strategic Research Report

Overview

Scope of the Report

Market Segmentation

Market Context

Competitive Landscape

What the Report Covers

Key Questions Answered

Who Can Use This Report

Segments covered in this report

Table of contents

Frequently asked questions

Research Methodology

Need a customized version?

Leading Brands in This Industry

Global Next Generation Drug Conjugates (NDCs) Market Strategic Research Report

Overview

Scope of the Report

Market Segmentation

Market Context

Competitive Landscape

What the Report Covers

Key Questions Answered

Who Can Use This Report

Segments covered in this report

Table of contents

Frequently asked questions

Research Methodology

Related reports

Global Peptide Market Strategic Intelligence Suite

Global Oncology Market Strategic Research Report

Global Peptide Therapy Market Strategic Research Report

Need a customized version?

Leading Brands in This Industry